Gensci-059 is under clinical development by Changchun GeneScience Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gensci-059’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gensci-059 overview
Gensci-059 is under development for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome and unspecified indication. It acts by targeting CD47. It is administered through parenteral route.
It was also under development for the treatment of non-Hodgkin lymphoma, advanced malignant solid tumors.
Changchun GeneScience Pharmaceutical overview
GeneScience Pharmaceuticals Co Ltd (GeneScience), a subsidiary of Changchun High-tech Industrial (Group) Co Ltd, provides genetically engineered pharmaceutical products. The company offers products in various therapeutic areas such as assisted reproduction, growth and development, tumor, immune, antiviral and metabolic diseases. It provides child health science, wound healing and women health products. GeneScience sells its products under the brand names JINTROLONG, JINTROPIN, GENFULIN and JINFOLLIN. The company operates a marketing office in Shanghai, and research and development centers in Changchun, Shanghai and Beijing, China. GeneScience Pharmaceuticals is headquartered in Changchun, Jilin, China.
For a complete picture of Gensci-059’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.